Please Wait.....

Report

Asia-Pacific Insulin Market for Type 1 and Type 2 Diabetes

Market Report I 2025-04-01 I 350 Pages I Data Bridge Market Research

Asia-Pacific insulin market for type 1 and type 2 diabetes market is expected to reach USD 5.75 billion by 2032 from USD 3.88 billion in 2024, growing at the CAGR of 5.1% in the forecast period of 2025 to 2032.

Market Segmentation:
Asia-Pacific Insulin Market for Type 1 And Type 2 Diabetes Segmentation, Type (Type 2 Diabetes and Type 1 Diabetes), Product Type (Long Acting Insulin, Rapid-Acting Insulin, Short Acting Insulin, and Others), Absorption Site (Basal, Bolus, and Others), Age Group (Adult Patients, Geriatric Patients, and Pediatric Patients), Source (Analog Insulin, Human Insulin, and Others), Delivery Method (Insulin Pens, Vial & Syringe, Insulin Pumps, Inhalable Insulin, and Implantable Insulin Delivery Systems), Gender (Male and Female), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies, and Diabetes Clinics & Specialty Pharmacies), By Countries (China, India, Japan, South Korea, Singapore, Thailand, Malaysia, Indonesia, Australia, Philippines, New Zealand, Taiwan, Vietnam, and rest of Asia-Pacific)- Industry Trends and Forecast to 2032

Overview of Asia-Pacific Insulin Market for Type 1 and Type 2 Diabetes Dynamics:

Driver

- Rising prevalence of diabetes
Restraint

- Adverse effects of high dosage of insulin

Opportunity

- Advancements in insulin formulation and delivery technologies
Market Players:

The key market players operating in the Asia-Pacific insulin market for type 1 and type 2 diabetes are listed below:

- Novo Nordisk A/S (Denmark)
- Eli Lilly and Company (U.S.)
- Sanofi (France)
- Biocon (India)
- Lupin (India)
- Shanghai Fosun Wanbang (Jiangsu)
- Pharmaceutical Group Co., Ltd. (China)
- Diasome Pharmaceuticals, Inc. (U.S.)
- SciGen Pte. Ltd. (Singapore)
- Wockhardt (India)
- MJ Biopharma Pvt. Ltd. (India)
- Oramed Pharmaceuticals (U.S.)
- Adocia (France)
- Nektar Therapeutics (U.S.)

TABLE OF CONTENTS
1 INTRODUCTION 13
1.1 OBJECTIVES OF THE STUDY 13
1.2 MARKET DEFINITION 13
1.3 OVERVIEW OF THE ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 13
1.4 LIMITATIONS 15
1.5 MARKETS COVERED 15
2 MARKET SEGMENTATION 18
2.1 MARKETS COVERED 18
2.2 GEOGRAPHICAL SCOPE 19
2.3 YEARS CONSIDERED FOR THE STUDY 20
2.4 CURRENCY AND PRICING 20
2.5 DBMR TRIPOD DATA VALIDATION MODEL 21
2.6 MULTIVARIATE MODELLING 24
2.7 TYPE LIFELINE CURVE 24
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 25
2.9 DBMR MARKET POSITION GRID 26
2.10 SECONDARY SOURCES 28
2.11 ASSUMPTIONS 28
3 EXECUTIVE SUMMARY 29
4 PREMIUM INSIGHTS 34
4.1 PESTAL ANALYSIS 35
4.2 PORTERS FIVE FORCES ANALYSIS 36
4.3 EPIDEMIOLOGY 37
4.4 INDUSTRY INSIGHTS 42
4.5 KEY MARKETING STRATEGIES FOR THE ASIA-PACIFIC ORAL INSULIN MARKET (TYPE 1 & TYPE 2 DIABETES) 48
4.6 MERGERS AND ACQUISITION 50
4.7 PIPELINE ANLYSIS 51
5 REGULATORY 53
5.1 REGULATORY FRAMEWORK FOR THE ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 53
5.1.1 REGULATORY APPROVAL PROCESS 53
5.1.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 54
5.1.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 54
5.1.4 LICENSING AND REGISTRATION 54
5.1.5 POST-MARKETING SURVEILLANCE 55
5.1.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 55
5.2 REGULATORY FRAMEWORK FOR THE NORTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 56
5.2.1 REGULATORY APPROVAL PROCESS 56
5.2.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 57
5.2.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 57
5.2.4 LICENSING AND REGISTRATION 57
5.2.5 POST-MARKETING SURVEILLANCE 57
5.2.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 58
5.3 REGULATORY FRAMEWORK FOR THE SOUTH AMERICA ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 59
5.3.1 REGULATORY APPROVAL PROCESS 59
5.3.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 59
5.3.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 60
5.3.4 LICENSING AND REGISTRATION 61
5.3.5 POST-MARKETING SURVEILLANCE 61
5.3.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 61
5.4 REGULATORY FRAMEWORK FOR THE EUROPE ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 62
5.4.1 REGULATORY APPROVAL PROCESS 62
5.4.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 62
5.4.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 63
5.4.4 LICENSING AND REGISTRATION 64
5.4.5 POST-MARKETING SURVEILLANCE 64
5.4.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 64
5.5 REGULATORY FRAMEWORK FOR THE MIDDLE EAST & AFRICA (MEA) ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES 65
5.5.1 REGULATORY APPROVAL PROCESS 65
5.5.2 GEOGRAPHIES' EASE OF REGULATORY APPROVAL 65
5.5.3 REGULATORY APPROVAL PATHWAYS (COUNTRY-WISE) 66
5.5.4 LICENSING AND REGISTRATION 67
5.5.5 POST-MARKETING SURVEILLANCE 67
5.5.6 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES 68
6 MARKET OVERVIEW 73
6.1 DRIVERS 75
6.1.1 GROWING INCIDENCE OF DIABETES WORLDWIDE 75
6.1.2 GROWING GERIATRIC POPULATION ENCOURAGING DEMAND FOR NON-INVASIVE DIABETES SOLUTIONS 76
6.1.3 ADVANCEMENTS IN ORAL INSULIN FORMULATIONS 77
6.1.4 ENHANCED PATIENT COMPLIANCE AND CONVENIENCE WITH ORAL INSULIN 78
6.2 RESTRAINTS 79
6.2.1 ADVERSE EFFECTS OF HIGH DOSAGE OF INSULIN 79
6.2.2 HIGH PRODUCTION AND DEVELOPMENT COSTS ASSOCIATED WITH INSULIN 79
6.3 OPPORTUNITIES 81
6.3.1 ADVANCEMENTS IN ORAL INSULIN DELIVERY TECHNOLOGIES 81
6.3.2 REVOLUTIONIZING DIABETES MANAGEMENT WITH NEEDLE-FREE ORAL INSULIN 82
6.3.3 INCREASING PHARMACEUTICAL INVESTMENTS AND STRATEGIC COLLABORATIONS 83
6.4 CHALLENGES 84
6.4.1 INSULIN ACCESSIBILITY CHALLENGES IN RURAL AND UNDERSERVED REGIONS 84
6.4.2 LIMITED SHELF LIFE ASSOCIATED WITH ORAL INSULIN 84
7 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY TYPE 86
7.1 OVERVIEW 87
7.2 TYPE 2 DIABETES 90
7.3 TYPE 1 DIABETES 90
8 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY TECHNOLOGY 91
8.1 OVERVIEW 92
8.2 POLYMERIC NANOPARTICLES 95
8.3 NANOPARTICLE-BASED DELIVERY SYSTEMS 95
8.4 ENCAPSULATION TECHNOLOGY 96
8.5 LIPID-BASED NANOCARRIERS 96
9 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY PRODUCT TYPE 97
9.1 OVERVIEW 98
9.2 CAPSULES 101
10 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY ABSORPTION SITE 102
10.1 OVERVIEW 103
10.2 INTESTINAL 106
11 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY FORMULATION TYPE 107
11.1 OVERVIEW 108
11.2 ENTERIC-COATED ORAL INSULIN 111
12 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY AGE GROUP 112
12.1 OVERVIEW 113
12.2 ADULT PATIENTS 116
12.3 GERIATRIC PATIENTS 116
12.4 PEDIATRIC PATIENTS 117
13 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY GENDER 118
13.1 OVERVIEW 119
13.2 MALE 122
13.3 FEMALE 122
14 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES MARKET, BY DISTRIBUTION CHANNEL 123
14.1 OVERVIEW 124
14.2 RETAIL PHARMACIES 127
14.3 HOSPITAL PHARMACIES 127
14.4 ONLINE PHARMACIES 128
14.5 DIABETES CLINICS & SPECIALTY PHARMACIES 128
15 ASIA-PACIFIC ORAL INSULIN MARKET FOR TYPE 1 AND TYPE 2 DIABETES, BY REGION 129
15.1 ASIA-PACIFIC 131
15.1.1 CHINA 131
15.1.2 INDIA 131
15.1.3 JAPAN 131
15.1.4 SOUTH KOREA 131
15.1.5 AUSTRALIA 131
15.1.6 INDONESIA 131
15.1.7 THAILAND 131
15.1.8 MALAYSIA 131
15.1.9 VIETNAM 131
15.1.10 PHILIPPINES 131
15.1.11 TAIWAN 132
15.1.12 SINGAPORE 132
16 COMPANY PROFILE 133
16.1 APHIOS CORPORATION 133
16.1.1 COMPANY SNAPSHOT 133
16.1.2 PIPELINE PORTFOLIO 133
16.1.3 RECENT UPDATES 133
16.2 BIOCON 134
16.2.1 COMPANY SNAPSHOT 134
16.2.2 REVENUE ANALYSIS 134
16.2.3 PIPELINE PRODUCT PORTFOLIO 135
16.2.4 RECENT DEVELOPMENT 135
16.3 DIABETOLOGY LTD 136
16.3.1 COMPANY SNAPSHOT 136
16.3.2 PIPELINE PORTFOLIO 136
16.3.3 RECENT UPDATES 136
16.4 ENDO AXIOM 137
16.4.1 COMPANY SNAPSHOT 137
16.4.2 PIPELINE PORTFOLIO 137
16.4.3 RECENT DEVELOPMENTS 137
16.5 MURLI KRISHNA PHARMA 138
16.5.1 COMPANY SNAPSHOT 138
16.5.2 PIPELINE PORTFOLIO 138
16.5.3 RECENT UPDATES 138
16.6 NIEDLFREE 139
16.6.1 COMPANY SNAPSHOT 139
16.6.2 PIPELINE PORTFOLIO 139
16.6.3 RECENT UPDATES 139
16.7 ORAMED 140
16.7.1 COMPANY SNAPSHOT 140
16.7.2 REVENUE ANALYSIS 140
16.7.3 PIPELINE PRODUCT PORTFOLIO 141
16.7.4 RECENT DEVELOPMENT 141
16.8 TRANSGENE BIOTEK LIMITED 142
16.8.1 COMPANY SNAPSHOT 142
16.8.2 REVENUE ANALYSIS 142
16.8.3 PIPELINE PORTFOLIO 143
16.8.4 RECENT DEVELOPMENT 143
17 QUESTIONNAIRE 144
18 RELATED REPORTS 147
?

Not Sure / Need Reassuring
- Confirm Content
  - Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
    
    Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
    
    Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
    
    Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
- Sample Pages
  - With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
    
    It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
    
    To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Check for Alternatives
  - Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
    
    To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
Prices / Formats / Delivery
- Prices
  - All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
    
    Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Discounts
  - As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
    
    Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
    
    To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
- Available Currencies
  - Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
    
    Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
    
    To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
- Licenses
  - License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Global Site License
  - The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
    
    It is important to note that this may exclude Parent Companies or Subsidiaries.
    
    If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
- Formats
  - The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
    
    If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
- Delivery
  - Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
    
    Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
    
    If a delay in delivery is expected you will be informed about it immediately.
- Shipping Charges
  - As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
    
    If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
Ordering
- By Credit Card
  - We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
    
    Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
    
    For more information on PayU please visit: https://www.payu.pl/en/about-us
- By Money Transfer
  - If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
    
    With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
Security
- Website security
  - We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
    
    Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
- Credit Card Security
  - We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
    
    PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.